The office building of international biopharmaceutical company AstraZeneca.

Cfoto | Future Publishing | Getty Images

AstraZeneca on Monday announced plans to invest $50 billion in enhancing its U.S. manufacturing and research capabilities by 2030, becoming the latest pharmaceutical firm to increase its domestic spending in response to U.S. trade tariffs. The Anglo-Swedish biotech company, based in Cambridge, England, stated that the “cornerstone” of this commitment would be a new multi-billion dollar facility dedicated to producing its weight management and metabolic portfolio, which includes its oral GLP-1 obesity pill.

Planned for the Commonwealth of Virginia, this facility is set to be AstraZeneca’s largest single manufacturing investment globally and will “leverage AI, automation, and data analytics to optimize production,” according to the company. This new funding will also expand research and development and cell therapy manufacturing in Maryland, Massachusetts, California, Indiana, and Texas, creating “tens of thousands of jobs,” AstraZeneca added.

CEO Pascal Soriot emphasized that this commitment underscores the firm’s “belief in America’s innovation in biopharmaceuticals” and supports its goal of achieving $80 billion in annual revenue by 2030, with half anticipated to come from the U.S. AstraZeneca, which gained international recognition for developing one of the key Covid-19 vaccines, has long focused on the U.S. market. In 2024, the United States accounted for over 40% of the company’s annual revenues.

In November, shortly after the U.S. presidential election, AstraZeneca announced a $3.5 billion investment in the U.S. Earlier this month, a report indicated that the firm may consider moving its listing from London to the U.S., which analysts suggest could significantly impact the U.K.’s public markets. AstraZeneca is currently the most valuable business listed on London’s FTSE 100, and the company declined to comment on the recent report.

Pharma firms ramp up U.S. spending

AstraZeneca’s funding announcement aligns with similar commitments from other global pharmaceutical companies, including Novartis, Sanofi, Roche, and U.S.-headquartered Eli Lilly and Johnson & Johnson. These firms have pledged to increase their investments in the U.S. in light of demands for reshoring domestic manufacturing. The industry is awaiting further clarity on ongoing pharmaceutical tariffs, with the final findings from a Section 232 investigation into the sector expected at the end of this month. Additionally, efforts are underway to address discrepancies in U.S. drug prices compared to those in other countries.

Recently, there were indications that the industry could face tariffs of up to 200%, with a brief grace period for firms to relocate manufacturing. However, many industry leaders and analysts consider this timeframe insufficient. “Typically for most medicines, it’s a three to four year horizon. We’re working very hard to accelerate that as fast as we can and demonstrate we’re making the investments we have planned,” remarked Novartis CEO Vas Narasimhan during a recent earnings call, expressing hope that the administration would provide necessary allowances.